Cargando…

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) has one of the most hypoxic and immunosuppressive tumor microenvironments (TME) among solid tumors. However, there is no proven therapeutic strategy to remodel the TME to be less hypoxic and proinflammatory. In this study, we classified tumors according...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhary, Ritu, Slebos, Robbert J.C., Noel, Leenil C., Song, Feifei, Poole, Maria I., Hoening, Dirk S., Hernandez-Prera, Juan C., Conejo-Garcia, Jose R., Guevara-Patino, Jose A., Wang, Xuefeng, Xie, Mengyu, Tan, Aik Choon, Chung, Christine H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202124/ https://www.ncbi.nlm.nih.gov/pubmed/37377902 http://dx.doi.org/10.1158/2767-9764.CRC-22-0443

Ejemplares similares

Deep Learning of Histopathology Images at the Single Cell Level
por: Lee, Kyubum, et al.
Publicado: (2021)

lncDIFF: a novel quasi-likelihood method for differential expression analysis of non-coding RNA
por: Li, Qian, et al.
Publicado: (2019)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

A reporter system for translational readthrough of stop codons in human cells
por: Halvey, Patrick J., et al.
Publicado: (2012)

Amantadine as a Potential Treatment for Marchiafava–Bignami Disease: Case Reports and a Possible Mechanism
por: Noel, Leenil, et al.
Publicado: (2022)

Corrigendum: Proteomic analysis of colon and rectal carcinoma using standard and customized databases
por: Slebos, Robbert J.C., et al.
Publicado: (2015)

Proteomic analysis of colon and rectal carcinoma using standard and customized databases
por: Slebos, Robbert J.C., et al.
Publicado: (2015)

Enabling proteomics-based identification of human cancer variations
por: Li, Jing, et al.
Publicado: (2010)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma
por: Hatakeyama, Hiromitsu, et al.
Publicado: (2010)

Cysteinyl Peptide Capture for Shotgun Proteomics: Global Assessment of Chemoselective Fractionation
por: Lin, De, et al.
Publicado: (2010)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Comparison of Protein Immunoprecipitation-Multiple Reaction Monitoring with ELISA for Assay of Biomarker Candidates in Plasma
por: Lin, De, et al.
Publicado: (2013)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
por: Goulet, Dennis R., et al.
Publicado: (2022)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
por: Chung, Christine H., et al.
Publicado: (2021)

PTEN status in advanced colorectal cancer treated with cetuximab
por: Negri, F V, et al.
Publicado: (2010)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
por: De Vita, F, et al.
Publicado: (2011)

Proteomic Consequences of a Single Gene Mutation in a Colorectal Cancer Model
por: Halvey, Patrick J., et al.
Publicado: (2011)

Global Stability of Plasma Proteomes for Mass Spectrometry-Based Analyses
por: Zimmerman, Lisa J., et al.
Publicado: (2012)

Prospective practice survey of management of cetuximab-related skin reactions
por: Lugtenberg, R. T., et al.
Publicado: (2020)

Cetuximab in small bowel adenocarcinoma: a new friend?
por: Santini, D, et al.
Publicado: (2010)

Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells
por: FUKUDA, KAZUMASA, et al.
Publicado: (2011)

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
por: Zhang, Lianhai, et al.
Publicado: (2013)

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer
por: Yang, Guang, et al.
Publicado: (2021)

Integrative Omics Analysis Reveals the Importance and Scope of Translational Repression in microRNA-mediated Regulation
por: Liu, Qi, et al.
Publicado: (2013)

proBAMsuite, a Bioinformatics Framework for Genome-Based Representation and Analysis of Proteomics Data
por: Wang, Xiaojing, et al.
Publicado: (2016)

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
por: Marzi, L, et al.
Publicado: (2016)

Cetuximab in Refractory Skin Cancer Treatment
por: Kalapurakal, Sini J, et al.
Publicado: (2012)

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
por: Concha-Benavente, Fernando, et al.
Publicado: (2014)

Transgenic goats producing an improved version of cetuximab in milk
por: Laible, Götz, et al.
Publicado: (2020)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Virtual alignment of pathology image series for multi-gigapixel whole slide images
por: Gatenbee, Chandler D., et al.
Publicado: (2023)

Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy
por: Gupta, Deepak, et al.
Publicado: (2011)

Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma
por: Janmaat, Vincent T., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_li73r40u9gbhn337rpc7hesr2e